CA2542277A1 - Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith - Google Patents

Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith Download PDF

Info

Publication number
CA2542277A1
CA2542277A1 CA002542277A CA2542277A CA2542277A1 CA 2542277 A1 CA2542277 A1 CA 2542277A1 CA 002542277 A CA002542277 A CA 002542277A CA 2542277 A CA2542277 A CA 2542277A CA 2542277 A1 CA2542277 A1 CA 2542277A1
Authority
CA
Canada
Prior art keywords
trifluoromethyl
carboxylic acid
benzopyran
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542277A
Other languages
English (en)
French (fr)
Inventor
Walter G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia Corporation
Walter G. Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation, Walter G. Smith filed Critical Pharmacia Corporation
Publication of CA2542277A1 publication Critical patent/CA2542277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002542277A 2003-10-21 2004-10-21 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith Abandoned CA2542277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51309903P 2003-10-21 2003-10-21
US60/513,099 2003-10-21
PCT/US2004/034685 WO2005041864A2 (en) 2003-10-21 2004-10-21 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method

Publications (1)

Publication Number Publication Date
CA2542277A1 true CA2542277A1 (en) 2005-05-12

Family

ID=34549248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542277A Abandoned CA2542277A1 (en) 2003-10-21 2004-10-21 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith

Country Status (6)

Country Link
EP (1) EP1691797A2 (es)
JP (1) JP2007509154A (es)
BR (1) BRPI0415753A (es)
CA (1) CA2542277A1 (es)
MX (1) MXPA06004499A (es)
WO (1) WO2005041864A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0218868D0 (en) 2002-08-14 2002-09-25 Nasir Muhammed A Improved airway management device
ATE447555T1 (de) 2003-03-10 2009-11-15 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
EP1755595A1 (en) * 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
EP2258350B1 (en) 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
EP2547335A4 (en) * 2010-03-15 2014-04-16 Univ Virginia Commonwealth AEROSOLIC DAPSONE AS THERAPY AGAINST INFLAMMATION OF THE RESPIRATORY SYSTEM AND ANOMALY OF MUCOCILIARY TRANSPORT
GB201010647D0 (en) 2010-06-24 2010-08-11 Docsinnovent Ltd Stopper device
GB201201438D0 (en) 2012-01-27 2012-03-14 Docsinnovent Ltd Improved stopper device
USD761952S1 (en) 2012-07-27 2016-07-19 Docsinnovent Limited Airway device
WO2013131255A1 (en) * 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
EP2846793A1 (en) * 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
WO2014026959A1 (en) * 2012-08-13 2014-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
GB2521375C (en) 2013-12-17 2021-09-29 Aslam Nasir Muhammed Intubating Airway Device
USD842456S1 (en) 2015-12-15 2019-03-05 Intersurgical Ag Airway device
GB201720733D0 (en) 2017-12-13 2018-01-24 Ashkal Development Ltd Airway device
EP4069213A1 (en) * 2019-12-03 2022-10-12 The USA, as represented by The Secretary, Department of Health and Human Services Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
US20230073803A1 (en) * 2019-12-16 2023-03-09 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase - 2 inhibitors
USD1025348S1 (en) 2020-04-16 2024-04-30 Intersurgical Ag Airway device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
AU1930301A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Valdecoxib compositions
TWI256305B (en) * 2000-08-18 2006-06-11 Pharmacia Corp Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
PT1429807E (pt) * 2001-09-19 2007-05-31 Altana Pharma Ag Combinação de um nsaid e de um inibidor de pde-4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2

Also Published As

Publication number Publication date
EP1691797A2 (en) 2006-08-23
MXPA06004499A (es) 2006-06-27
WO2005041864A3 (en) 2006-05-18
BRPI0415753A (pt) 2006-12-19
WO2005041864A2 (en) 2005-05-12
JP2007509154A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
US20040204472A1 (en) Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2474016A1 (en) A combination for treating cold and cough
CA2556380A1 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
CA2472199A1 (en) Treatment involving peroxisome proliferator-activated receptor-gamma agonist and cyclooxygenase-2 selective inhibitors
CA2542277A1 (en) Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
US20030212138A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
WO2004093870A1 (en) Treatment and prevention of otic disorders
CA2457452A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
CA2457453A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
US20040220155A1 (en) Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20030207846A1 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
WO2005009340A2 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
WO2005049014A1 (en) Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
US20050004224A1 (en) Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
KR20040063112A (ko) 시클로옥시게나제-2 선택성 억제제 및 글루코사민을이용한 통증 및 염증의 치료 및 예방을 위한 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead